Cancer and Immunology · global
Selectively Activating T Cells: New Cancer Immunotherapy Shows Antitumor Signals in Early Trial
Invikafusp alfa aims to expand specific T-cell populations, seeking a path forward for patients with advanced cancer and limited treatment options. Initial human data support its mechanism of action, but how long tumor responses last and which patients truly benefit remain questions for subsequent trials.
How to remobilize immune cells when cancer stops responding to immunotherapy is a challenge in drug development. An early human trial co-led by Mass General Brigham showed that the experimental drug invikafusp alfa can expand specific T cells and produced signals of tumor shrinkage in some patients with advanced solid tumors and limited treatment options. The findings were published in *Nature Medicine* and presented at the 2026 European Society for Medical Oncology Congress.
The drug combines two stimulatory signals in a single molecule: one end recognizes the Vβ6/Vβ10 regions of the T-cell receptor, while the other provides interleukin-2 receptor signaling, with the aim of promoting proliferation of these T cells. The central research question is whether selectively stimulating a population of immune cells can achieve a better balance between antitumor activity and systemic immune responses.
The START-001 trial, sponsored by developer Marengo Therapeutics, enrolled 34 patients with advanced solid tumors in its Phase 1 dose-escalation stage, followed by 18 patients entering Phase 2. According to the company's announcement, the paper covers the completed Phase 1 stage and initial Phase 2 expansion cohorts; the study is ongoing, and these results cannot be considered the final conclusions of the Phase 2 trial.
According to the summary released by the institution, at what it described as the optimal dose, the disease control rate was 59.3%, and approximately 15% of patients experienced marked tumor shrinkage. Disease control includes tumors remaining stable and cannot be equated with tumor shrinkage, nor does it mean that prolonged survival has been demonstrated. The summary did not clearly specify the denominators used to calculate these two percentages, so they should not be applied directly to all 52 participants.
Biological analyses also supported the drug's design. According to the company's announcement, Vβ6/Vβ10 effector and memory T cells selectively expanded in both patients' blood and tumors; confirmed tumor responses included cases of microsatellite-stable colorectal cancer and PD-L1-negative non-small cell lung cancer. However, individual responses are insufficient to infer efficacy across an entire cancer type.
Regarding safety, the company stated that the maximum tolerated dose was not reached in Phase 1, and the research team selected the recommended Phase 2 dose based on safety, pharmacodynamic, and antitumor data. Cytokine release syndrome was mostly low grade, and no treatment-related deaths, treatment-related Grade 4 non-laboratory adverse events, or immune effector cell-associated neurotoxicity syndrome were reported. These findings support continued research, but a small trial still cannot readily rule out rare risks.
The next priorities are to establish the duration of responses and identify which patients are most likely to benefit. The current data are insufficient to establish a clinical advantage over existing treatments. Interpretation of the results also requires attention to the researchers' relationships with the company: Marengo provided trial support, some authors are company employees, and co-author Lillian Siu also serves as a scientific adviser to the company and holds equity. These findings provide human evidence for selectively mobilizing T cells, but further validation is needed to establish its therapeutic value.